RZLT News & Events

Cash, cash equivalents and investments in marketable securities were $120.3M as of March 31, compared with $167.9M as of June 30, 2025.

Rezolute announced that expanded analyses from the Phase 3 sunRIZE study of ersodetug in patients with congenital HI were presented at the Pediatric Endocrine Society 2026 Annual Meeting. The oral presentation was made by Diva De Leon-Crutchlow, Chief of the Division of Endocrinology and Diabetes, Director of the Congenital Hyperinsulinism Center at Children's Hospital of Philadelphia, and Principal Investigator of the sunRIZE study. In addition to the previously reported topline results, the presentation included additional results from pre-specified and post-hoc sunRIZE analyses, which the Company believes reiterates evidence of target engagement and highlights the potential therapeutic benefit of ersodetug. As discussed in today's presentation, although statistical significance for the secondary endpoint was not achieved at the Week 24/End of Treatment evaluation window, larger and often nominally statistically significant glycemic improvements were consistently observed throughout the maintenance dosing phase of the study, across time and numerous pre-specified and post-hoc CGM-based endpoints. Average daily percent time in hypoglycemia by CGM: clinically relevant and nominally statistically significant reductions of greater than50% and ~60-80%, compared to placebo across multiple timepoints. Average weekly hypoglycemia events by CGM: clinically relevant and nominally statistically significant reductions of ~50-65% and ~50-80%, compared to placebo across multiple timepoints. Average daily AUC 70 to 180 mg/dL by CGM: clinically relevant and nominally statistically significant increases of ~25-50%, compared to placebo across multiple timepoints. Average blood glucose by CGM: clinically relevant and nominally statistically significant increases of ~10-15% in both the FAS and PPS, compared to placebo across multiple timepoints. The Company is also assessing the longer-term efficacy and safety of ersodetug in a real-world setting in an ongoing OLE phase of the study, including the roll-over of placebo participants. Following the conclusion of the randomized and placebo-controlled phase of sunRIZE, all 59 study completers elected to enter the OLE, as previously reported by the Company. Reflecting no change since last reported, 57 participants continue to attend regular study visits at sunRIZE study centers to receive ersodetug in the OLE, now representing a cumulative ersodetug exposure duration in the study ranging from approximately 6 to 24 months. Preliminary OLE observations demonstrate continued glycemic benefit, including a clinically significant change in glycemic control in the rolled-over placebo participants compared to the controlled period of the study. These glycemic benefits have enabled a concurrent significant overall reduction in background SOC therapies, with a significant number of patients now receiving ersodetug as monotherapy. Notably, a summary of these same CGM-based study outcomes and preliminary observations from the OLE phase of the study were recently discussed with the U.S. Food and Drug Administration as part of the Company's Type B meeting held on March 17, 2026. The meeting resulted in the agency acknowledging challenges associated with the study primary endpoint and concluded with the agency requesting that the Company submit the broader study data for the agency's comprehensive evaluation to inform next steps for the program.

The major averages closed broadly higher following reports that the U.S. has provided a plan to Iran to bring the war to an end, which sent oil prices lower. The Associated Press reported that Iran was given a 15-point proposal from the U.S. to end the conflict, though media have reported that the two sides remain far apart on a resolution and attacks from both sides have continued.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:MerckTerns Pharmaceuticalsfor $53 per share in cashElon Musk's SpaceX will file an IPO prospectus as soon as this week or next,Armexpectsfrom its chips unit in five yearsChewyreportedand provided its outlook for Q1 and FY26JetBlueis exploring a potential merger with rivals,2. WALL STREET CALLS:Armto Outperform from Market Perform at Raymond JamesWolfeGeneral Motorson underappreciated potential tailwindsWedbushRezoluteas worst case scenario seems unlikely for cHIMondelezto Neutral from Buy at Rothschild & Co RedburnEVgowith Neutral from Overweight at JPMorgan3. AROUND THE WEB:Salesforceis skipping raises for its director-level and above employees, Insider reportsA jury found Metaand Googleliable in a social media addiction trial, Reuters saysMeanwhile, Metawill lay off "a few hundred people" across the company on Wednesday, The Information saysSK Hynixplans to spend about $8B on cutting-edge EUV lithography chipmaking tools from ASMLthrough 2027, Bloomberg saysInteland AMDhave each told customers they plan to raise prices across their entire CPU product lines starting in March and April, Nikkei reports4. MOVERS:Sareptarose after announcingfrom Phase 1/2 ascending dose studies of SRP-1001 and SRP-1003Brazegained afterand authorizing a stock repurchase program of up to $100MApogee Therapeuticsfinished higher after announcing aMaze Therapeuticsclosed lower afterand announcing data from its Phase 2 HORIZON trialAdma Biologicsfell for another session afterfrom Culper Research5. EARNINGS/GUIDANCE:Paychexand reaffirmed its guidance for FY26EDAP TMSand backed its guidance for FY26Cognyte, with EPS beating consensusCintasand raised its guidance for FY26QT Imagingand reaffirmed guidance for FY26INDEXES:The Dow rose 305.43, or 0.66%, to 46,429.49, the Nasdaq gained 167.93, or 0.77%, to 21,929.83, and the S&P 500 advanced 35.53, or 0.54%, to 6,591.90.

The major averages were broadly higher near noon following reports that the U.S. has provided a plan to Iran to bring the war to an end, which sent oil prices lower. The Associated Press reported that Iran was given a 15-point proposal from the U.S. to end the conflict, though media have reported that the two sides remain very far apart and attacks from both sides have continued.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:MerckTerns Pharmaceuticalsfor $53 per share in cashElon Musk's SpaceX will file an IPO prospectus as soon as this week or next,Armexpectsfrom its chips unit in five yearsChewyreportedand provided its outlook for Q1 and FY26Beretta willfor 20.05% of Sturm Rugershares2. WALL STREET CALLS:Armto Outperform from Market Perform at Raymond JamesWolfeGeneral Motorson underappreciated potential tailwindsWedbushRezoluteas worst case scenario seems unlikely for cHIMondelezto Neutral from Buy at Rothschild & Co RedburnEVgowith Neutral from Overweight at JPMorgan3. AROUND THE WEB:Finland has suspended a plan to move its election platform to Amazon Web Services, opting to remain on domestic servers through the 2027 general election, Bloomberg reportsSK Hynixplans to spend about $8B on cutting-edge EUV lithography chipmaking tools from ASMLthrough 2027, Bloomberg saysClear Secureapp downloads have surged, with passengers downloading the app 289,000 times since the beginning of March, as travelers face long TSA lines amid a partial government shutdown, WSJ reportsInteland AMDhave each told customers they plan to raise prices across their entire CPU product lines starting in March and April, Nikkei reportsMeta Platformswill lay off "a few hundred people" across the company on Wednesday, The Information says4. MOVERS:Sareptaincreases after announcingfrom Phase 1/2 ascending dose studies of SRP-1001 and SRP-1003Brazegains afterand authorizing a stock repurchase program of up to $100MApogee Therapeuticshigher after announcing aMaze Therapeuticslower afterand announcing data from its Phase 2 HORIZON trialAdma Biologicsfalls after addressing the5. EARNINGS/GUIDANCE:Paychexand reaffirmed its guidance for FY26EDAP TMSand backed its guidance for FY26Cognytewith EPS beating consensusCintasand raised its guidance for FY26QT Imagingand reaffirmed guidance for FY26INDEXES:Near midday, the Dow was up 0.62%, or 287.95, to 46,412.01, the Nasdaq was up 0.80%, or 173.04, to 21,934.94, and the S&P 500 was up 0.59%, or 38.91, to 6,595.28.